Dear Investor,
Our stock ratings have helped deliver major profits for investors in the field of AI.
Take Nvidia, for example, the biggest AI chipmaker.
In the first half of 2023, after Wall Street finally discovered it, Nvidia shares rose 191%, truly a big win.
But our Weiss stock ratings identified Nvidia as a “Buy” way back in 2011, and investors who bought it then could have seen gains of 9,624%.
Meanwhile, investors who recently bought another AI stock based on our “Buy” rating could have enjoyed gains of 810%. That was ASML.
On Lam Research, they could have done even better: gains of 3,146%.
And if folks bought Ansys when we first recommended it, they’d be up 5,466%.
What has driven this explosion in AI profits? Recently, it was mostly ChatGPT, an app that reached 100 million users in just two months flat.
That’s 15 times faster than Instagram, 27 times faster than Facebook and 96 times faster than smartphones.
In fact, it’s faster than any app in history.
I’m proud to say we were there first. And today, I’m especially proud to announce that we’re among the first to introduce the next major opportunity …
AI-Powered Healthcare, 100 Times
Bigger Than ChatGPT
This is not idle speculation.
It’s based on the proven fact that AI tech is already transforming the healthcare sector, and …
The proven fact that the sector is already 100x larger than generative AI, including ChatGPT.
Provided you jump here now, you can immediately download all the info you need to help you get started.
Bloomberg says the current AI breakthroughs — things like ChatGPT — will help investors make billions of dollars.
Good.
But our research tells us that healthcare AI is going to do much better than that. It’s going to SAVE billions of LIVES.
And when people do good for mankind, they naturally do well for themselves as well.
That’s why a recent article in Forbes says the new AI breakthroughs we cover in these bonus reports will not only save billions of lives …
They could also create the world’s first trillionaires.
According to a just-released study by Goldman Sachs, healthcare is especially ripe for disruption by artificial intelligence.
In fact, it was the first large industry to use artificial intelligence in a major way.
It already had the Big Data that AI needs.
It already had the precision instruments that could be programmed with AI.
And it always had the urgent need: to help save lives!
Healthcare is also an industry where our Weiss stock ratings have beaten every other analyst and algorithm we know of.
Since we first issued “Buy” ratings on the nation’s most promising healthcare companies, investors could have seen …
In your bonus reports, we give you our picks for the best AI-based healthcare investments for 2023 and beyond.
But for now, let me say this: Even the worst performer on our early “Buy” list, Pfizer, is up 179%, or nearly triple your money.
In total, in the first three years of our Weiss stock ratings, we gave “Buy” ratings to 34 healthcare companies, which we’ve never since downgraded to a “Sell.”
On these 34 stocks we picked, investors could have seen average gains of 2,245%, or more than 23 times their money. Of course, losses are always possible, but in this set of 34 companies, there were none.
Moreover, these results are not taken from some hypothetical, “backtested” model. We’ve been using it in real time for over 20 years.
It has stood the test of time, and it works.
It works because it’s not based on hearsay or some particular investment “philosophy.” It’s based on the data and nothing but the data.
And it works because, unlike the top Wall Street firms and ratings agencies, we never have accepted — and we never will accept — a dime of direct or indirect compensation from any company we rate.
We have no conflicts of interest at all. And this is why, unlike Wall Street, which gives out “Buy” ratings like candy, we’re tough.
As soon as any company fails our tough tests, we’re usually the first — and sometimes the only — rating agency to issue a “Sell” rating.
This independence, combined with our track record of success, is why I say investors can trust our top picks for the AI revolution that’s now sweeping through the healthcare industry.
It also helps explain why The Wall Street Journal has reported that our Weiss stock ratings ranked #1 for profit performance.
In fact, The Wall Street Journal showed that investors who followed our ratings could have made more money than investors who followed Goldman Sachs, JPMorgan, Merrill Lynch, Standard & Poor’s and all the 27 major Wall Street firms reviewed.
Now, it’s time for you to harness our expertise applied to AI opportunities and grab the chance to …
Grow Your Wealth Rapidly in
the AI Tech Explosions
To achieve this goal, you need to strike while the trend is still in its early stages like now.
You need to know which AI-related stocks are just hype and fluff …
Which AI stocks have already seen most of their gains …
And which ones we believe are now on the verge of leading the second phase of this great transformation.
That’s why I’ve arranged for you to receive all the intelligence you urgently need with a series of custom benefits …
Benefit #1
Our four extremely timely bonus reports that you can download instantly today.
How to Invest in Revolutionary AI-Assisted Drug Discoveries (sold separately for $79)
In this report, author Jon Markman not only maps out the immense future potential of using AI to discover new pharmaceuticals …
He also names the one company that can give investors what he believes are the greatest, and safest, potential gains in this field.
This is the area that’s expected to grow at an annual rate of 39.9% over the next few years, almost 40% a year.
That means it could double in just two years or more, an extraordinary pace of growth.
It’s faster than the AI growth rate overall. And 5.6 times faster than the growth of semiconductors.
Indeed, you’d be hard-pressed to find any major segment in any industry that’s expected to grow that fast.
How to Ride the Boom in AI-Based Diagnostics (sold separately for $79)
AI will soon be able to detect subtle signs and image configurations in CT scans that doctors would otherwise miss.
It will be able to sift through blood samples with amazing speed and efficiency to find things that specialists could not find despite many years of training.
And AI-based personal apps will help millions of people diagnose (or at least get a good head start on the diagnostic process) common or even uncommon diseases.
All from the comfort of their own home.
In this just-released report, Jon Markman shows you why he predicts each of these new AI technologies is about to spark separate booms in the companies that make or service them — and he shows you precisely what to invest in now for each one.
How to Ride the Explosion in AI Surgical Technology (sold separately for $79)
It’s no coincidence that Intuitive Surgical — the company behind the surgical robot “da Vinci” and has performed more than 10 million surgeries in 67 countries — was on our “Buy” list right from the beginning, up 6,256% since then.
Nor should you be surprised to hear that Jon has been recommending it for a long time.
And now Jon says:
“If you think the 6,256% gain we’ve seen since our ‘Buy’ rating for Intuitive Surgical was a stroke of luck, wait till you see how much the shares of these kinds of companies could surge when they do just one thing: when they marry tried-and-tested surgical hardware with the newest AI software.”
In this report, Jon identifies the best of the best. Plus, he explains how savvy investors can get in on this kind of opportunity before anyone else.
EXTRA BONUS: The Secret AI Weapon Behind Nvidia (sold separately for $79)
This is about an off-the-radar — but rapidly rising — AI chip designer that’s at the heart of of future AI processors. You’ve seen the historic growth and buzz around Nvidia. Well, the fact is, Nvidia can’t do it alone, and, as you’ll see in this extra bonus report, the deal this company just signed with Nvidia is the proof.
It’s already transforming the way Nvidia makes chips. And I think their partnership is just warming up.
By joining me today, you also get …
Get Everything for Just $78
![Bundle]()
That’s right. Bought separately, everything included in your Disruptors & Dominators membership would cost $703.
However, when you claim your membership today, you won’t have to invest anything close to that.
You can get everything for just $78.
And you promptly receive our email to with everything you need to download all your reports.
Then, as they are published, you’ll receive your copies of each and every Disruptors & Dominators newsletter.
I’m also making sure you are completely satisfied with everything you receive. That’s why …
I’m Offering a 100% Satisfaction Guarantee
I am giving you a full year to review everything you get in your entire Disruptors & Dominators membership package …
You will have 365 days to dive into all the special reports you can download today … the 12 Disruptors & Dominators issues you’ll receive … the 53,000 Weiss ratings you can access 24/7 for the year … the 365 daily updates you receive … and much, much more.
If you’re not happy, for any reason, with your membership, simply contact my Member Care Team, and you’ll receive a prompt refund of every penny.
To get started, simply fill out the secure order form below. Once you do, you’ll receive an email confirming your order.
It will include our contact information in case you have any questions. You’ll also receive an email with your special download link and access to our ratings.
Safely and Securely Order Below
To order by phone, call 1-877-934-7778
(or +1 561-627-3300 from overseas)
| Membership Benefit |
Standard Membership |
| 12 Digital Monthly Issues of Disruptors & Dominators |
$78
($129 Value) |
$49
($129 Value) |
| 12 Print Monthly Issues of Disruptors & Dominators |
$0
($30 Value) |
— |
| How to Invest in Revolutionary AI-Assisted Drug Discoveries |
$0
($79 Value) |
$0
($79 Value) |
| How to Ride the Boom in AI-Based Diagnostics |
$0
($79 Value) |
$0
($79 Value) |
| How to Ride the Explosion in AI Surgical Technology |
$0
($79 Value) |
$0
($79 Value) |
| Bonus Report: The Secret AI Weapon Behind Nvidia |
$0
($79 Value) |
— |
| 24/7 standard Access to All 53,000 of Our Weiss Ratings |
$0
($288 Value) |
— |
| Weiss Ratings Daily E-Letter |
Priceless |
Priceless |
| Total Value |
$703 |
$366 |
| Member Cost |
$78  |
$49 |
| Member Savings |
$625 |
$317 |
Your Membership Selection